Research finds new therapy options for children with severe juvenile idiopathic arthritis

December 21, 2012, SickKids

Systemic juvenile idiopathic arthritis (SJIA) has long been considered a therapeutic orphan. Until now, the principal effective treatment has been high-dose steroids (prednisone) which are accompanied by several serious side effects. Newer treatments for other forms of JIA have not been as successful for the systemic subtype.

SJIA, an inflammatory disease, accounts for approximately 15 per cent of all children with there are currently approximately 60 children followed with SJIA at SickKids. , skin rashes, and swelling of the joints and inflammation of such as heart, liver, spleen and lymph nodes are some of the symptoms that children with SJIA face daily.

Two recent studies in the have assessed other treatment options for these patients and found two biologic drugs to be safe and effective therapies for children with SJIA. In both studies, many children who were treated with these drugs not only achieved a status of inactive disease (no fever, no ) but also showed a reduction or discontinuation steroid use.

Both international studies were conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), which the Rheumatology Faculty at The Hospital for Sick Children (SickKids) and University of Toronto are members of. Dr. Rayfel Schneider was one of the co-investigators of both of these studies and the lead SickKids investigator.

"This group of patients is typically very challenging to treat. This research is a major step towards improved therapy options that are safe and effective." says Dr. Rayfel Schneider, Staff Physician and Project Investigator in the Department of Rheumatology at SickKids. "No unanticipated side effects were observed and those that did occur are also seen with other medications in this class."

Each therapy works by blocking specific molecules that are involved in the development and persistence of inflammation. The molecules called Interleukin-6 and Interleukin-1 have been found to be central to the pathogenesis of SJIA.

In one of the randomized controlled trials, a biologic called tocilizumab was administered to target the Interleukin-6 receptor. This study provides the first evidence in a controlled setting involving a large number of patients from around the world that blocking the action of Interleukin-6 with tocilizumab is highly effective, and safe, in patients with severe and persistent SJIA. After one year of treatment, one third of the patients reached clinically inactive disease and approximately half had stopped taking oral corticosteroids. This study was conducted at 43 centres worldwide.

In the other study the efficacy and safety of a biologic called canakinumab was assessed. Canakinumab selectively binds to Interleukin-1 beta and inactivates the signaling that leads to inflammation. The study was divided into two clinical trials; the first to provide evidence that the drug is effective in controlling fever and arthritis, and the second to further investigate the efficacy and safety of canakinumab in SJIA with active systemic features and the ability to reduce the dose of prednisone. The study demonstrated that even a single injection of the drug can result in inactive disease in as few as 15 days among 32 per cent of the treated patients. And after just seven months of treatment the drug allowed for discontinuation of steroid treatment for 45 per cent of the patients.

Overall, both therapeutic approaches proved to be safe and effective. "This appears to be a major step forward in the treatment of with SJIA and may lead to a change in the outcome of a difficult-to-manage, and potentially fatal disease," says Dr. Schneider.

Explore further: Not all juvenile arthritis is the same

Related Stories

Not all juvenile arthritis is the same

October 22, 2012
Systemic juvenile idiopathic arthritis (SJIA) is currently classified as a subtype of juvenile idiopathic arthritis but with the addition of systemic inflammation often resulting in fever, rash and serositis. New research ...

Pulmonary complications often fatal in systemic JIA

November 19, 2012
(HealthDay)—Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment

May 30, 2012
A retrospective analysis of methotrexate (MTX) safety data found that injection of this disease-modifying anti-rheumatic drug (DMARD) was not superior to oral therapy in long-term treatment of patients with juvenile idiopathic ...

Children with juvenile arthritis have higher rates of bacterial infection

May 1, 2012
Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published ...

Recommended for you

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

November 20, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.

Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was ...

Study lists foods for fighting rheumatoid arthritis symptoms and progression

November 8, 2017
A list of food items with proven beneficial effects on the progression and symptoms of rheumatoid arthritis is provided in a new study published today in Frontiers in Nutrition. The authors suggest incorporating these foods ...

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.